Antengene Licenses ATG-201 to UCB in $1.1B Deal
Innovative biotech firm Antengene Corporation Limited has entered into a major global licensing agreement with biopharmaceutical company UCB to advance the development of ATG-201, a…
Read More...
Read More...
